Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593297 | 0.91 | BRAF (0.48) | KDRBRAFMAPK14TNNI3KTLR8 | |
| SCHEMBL3594514 | 0.90 | ALDH1A1 (0.52) | KDRTLR8KMT2AATMTLR7 | |
| SCHEMBL3587532 | 0.86 | HIF1A (0.46) | KDRKMT2AJAK2JAK1TYK2 | |
| SCHEMBL3604416 | 0.82 | GRM5 (0.48) | KMT2APTGES | |
| SCHEMBL4164494 | 0.81 | KDR (0.59) | KDRBRAFMAPK14TNNI3KPTGES | |
| SCHEMBL3601549 | 0.81 | KDR (0.54) | KDRBRAFMAPK14TNNI3KJAK2 | |
| SCHEMBL3605396 | 0.80 | KDR (0.54) | KDRBRAFMAPK14TNNI3KKMT2A | |
| SCHEMBL3588802 | 0.75 | KDR (0.53) | KDRTLR8KMT2AJAK2JAK1 | |
| SCHEMBL3594026 | 0.72 | CBLB (0.53) | KDRBRAFMAPK14TNNI3KTYK2 | |
| SCHEMBL13408241 | 0.72 | FAAH (0.55) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1643991-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004863-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 843/4885BRAF 1/4885MAPK14 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.